DMK Pharmaceuticals Corporation
LSE: 0A4X.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Eddie Wabern Glover
- Employees
- 11
- Headquarters
- San Diego, United States
- IPO year
- 2023
- Market cap
- $10.0
- Website
- https://www.dmkpharmaceuticals.com
Loading 0A4X…
Loading profile data…Frequently asked questions about 0A4X
What does DMK Pharmaceuticals Corporation (0A4X.L) do?
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products i...
Where does 0A4X.L trade?
DMK Pharmaceuticals Corporation (0A4X.L) trades on the London Stock Exchange.
What sector is 0A4X.L in?
DMK Pharmaceuticals Corporation (0A4X.L) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of DMK Pharmaceuticals Corporation?
Eddie Wabern Glover is the chief executive officer of DMK Pharmaceuticals Corporation (0A4X.L).
Where is DMK Pharmaceuticals Corporation headquartered?
DMK Pharmaceuticals Corporation is headquartered in United States.
Does 0A4X.L pay a dividend?
DMK Pharmaceuticals Corporation (0A4X.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0A4X.L go public?
DMK Pharmaceuticals Corporation (0A4X.L) completed its initial public offering in 2023.